BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297]
URL: https://www.wjgnet.com/1948-5182/full/v10/i11/297.htm
Number Citing Articles
1
Yen-Yang Chen, Chao-Long Chen, Chih-Che Lin, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yen-Hao Chen. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control StudyCancers 2021; 13(18): 4584 doi: 10.3390/cancers13184584
2
Marie Decraecker, Caroline Toulouse, Jean-Frédéric Blanc. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on LenvatinibCancers 2021; 13(24): 6310 doi: 10.3390/cancers13246310
3
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo. Management of Hepatocellular Carcinoma Recurrence after Liver TransplantationCancers 2021; 13(19): 4882 doi: 10.3390/cancers13194882